IDNNA, also known as 4-iodo-2,5-dimethoxy-N,N-dimethylamphetamine or as N,N-dimethyl-DOI, is a chemical compound of the phenethylamine, amphetamine, and DOx families. It is the N,N-dimethyl derivative of the psychedelic drug DOI.
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists IDNNA's dose as greater than 2.6mg orally and its duration as unknown. IDNNA produced no effects at tested doses. Higher doses were not assessed.
The chemical synthesis of IDNNA has been described.
Analogues of IDNNA include DOI, N-methyl-DOI, methyl-DOB (N-methyl-DOB), Beatrice (N-methyl-DOM), N-methyl-DOET, N-methyl-2C-I, and N-methyl-2C-B, among others.
IDNNA was first described in the scientific literature by Alexander Shulgin and colleagues in 1982. Subsequently, it was described in greater detail by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.
IDNNA is a controlled substance in Canada under phenethylamine blanket-ban language.
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.